You Should Watch These: Gilead Sciences (NASDAQ:GILD), Netflix (NASDAQ:NFLX), Zynerba Pharmaceuticals (NASDAQ:ZYNE), B2Gold Corp. (NYSEMKT:BTG)

On 18 March, Symantec Corporation (NASDAQ:SYMC) shares fell -0.69% and was closed at $18.60. SYMC EPS growth in last 5 year was 7.70%. Symantec Corporation (NASDAQ:SYMC) year to date (YTD) performance is 10.85%.

Symantec Corporation (NASDAQ:SYMC) declared a special dividend. Investors of record on Tuesday, March 8th will be paid a dividend of 4.00 per share on Tuesday, March 22nd. This represents a yield of 3.12%. The ex-dividend date of this dividend is Friday, March 4th.

Gilead Sciences Inc. (NASDAQ:GILD) shares moved up 0.83% in last trading session and ended the day at $90.27. GILD Gross Margin is 87.70% and its has a return on assets of 40.20%. Gilead Sciences Inc. (NASDAQ:GILD) quarterly performance is -12.23%.

On 15 March, Gilead Sciences Inc. (NASDAQ:GILD) has halted several patient studies of its cancer drug, Zydelig, because of increased risk of death and serious side effects.

Netflix, Inc. (NASDAQ:NFLX) caters to the Services space. It has a net profit margin of 1.80% and weekly performance is 3.54%. On the last day of trading company shares ended up at $101.12. Netflix, Inc. (NASDAQ:NFLX) distance from 50-day simple moving average (SMA50) is 12.26%.

On 19 March, Netflix, Inc. (NASDAQ:NFLX) will invest $90 million in the Max Landis scripted cop thriller starring Will Smith titled, Bright. Directed by David Ayer and co-starring Joel Edgerton, the fantastical film is one of the largest spec deals for a writer in years. Deadline reports the deal includes “north of $3M for the Landis script,” and is intended to launch a franchise. The film will cost around $45 million to shoot – half of that in production costs, and another half for talent – making this Netflix’s largest movie deal.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) shares increased 7.73% in last trading session and ended the day at $10.73. ZYNE has a return on assets of -43.30%. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) quarterly performance is -19.63%.

On 14 March, Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) reported financial results for the quarter and year ended December 31, 2015, and provided an overview of recent operational highlights. The Company ended 2015 with $41.5 million in cash and cash equivalents and believes its current cash position will support its operating plan through Phase 2 data readout for the five indications of ZYN002 and ZYN001.

B2Gold Corp. (NYSEMKT:BTG) caters to the Basic Materials space. Its weekly performance is 21.97%. On the last day of trading company shares ended up at $1.61. B2Gold Corp. (NYSEMKT:BTG) distance from 50-day simple moving average (SMA50) is 61.24%.

B2Gold Corp. (NYSEMKT:BTG) is pleased to announce that it has received approvals for Gold Prepaid Sales Financing Arrangements (“Prepaid Sales”) of up to $120 million, has signed a commitment letter to enter into a Euro equivalent of $81 million term mining Equipment Facility (“The Facility”) and has increased the size of the Otjikoto Equipment Loan Facility. All dollar figures are in United States dollars unless otherwise indicated.